Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

License, Clinical Trial and Sponsored Research Agreements (Tables)

License, Clinical Trial and Sponsored Research Agreements (Tables)

6 Months Ended

Jun. 30, 2020

License Agreements [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Schedule of license, clinical trial and sponsored research agreements

For the three and six months ended June 30, 2020 and 2019, the Company recorded the following expense in research and development for licenses acquired:


		For the three months ended June 30,						For the six months ended June 30,
($ in thousands)		2020			2019			2020			2019
City of Hope National Medical Center
CD123		$	334		$	—		$	334		$	250
CS1			—			200			—			200
IL13Rα2			333			—			333			—
Spacer			333			—			333			—
HER2			—			—			250			—
Fred Hutchinson Cancer Research Center - CD20			300			—			300			—
Nationwide Children's Hospital - C134			—			—			—			200
Total		$	1,300		$	200		$	1,550		$	650

Sponsored Research And Clinical Trial Agreements

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Schedule of license, clinical trial and sponsored research agreements


		For the three months ended June 30,						For the six months ended June 30,
($ in thousands)		2020			2019			2020			2019
City of Hope National Medical Center			—			500			500			1,000
CD123			65			456			296			759
IL13Rα2			234			225			326			567
Manufacturing			—			115			—			229
CS1			770			—			770			—
Fred Hutchinson Cancer Research Center - CD20			189			374			716			641
St. Jude Children's Research Hospital - XSCID			1,558			—			1,558			—
Beth Israel Deaconess Medical Center - CRISPR			—			—			—			69
Total			2,816			1,670			4,166			3,265